Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman, Sara Ek
Dyk ned i forskningsemnerne om 'Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity'. Sammen danner de et unikt fingeraftryk.